https://www.selleckchem.com/pr....oducts/s-2-hydroxysu
These results confirm that C3 rather than C5 could be an effective therapeutic target to treat early AMD.Alternative splicing (AS) events associated with oncogenic processes present anomalous perturbations in many cancers, including ovarian carcinoma. There are no reliable features to predict survival outcomes for ovarian cancer patients. In this study, comprehensive profiling of AS events was conducted by integrating AS data and clinical information of ovarian serous cystadenocarcinoma (OV). Survival-related AS events
Like
Comment
Share
